4/A: Director Neal Amends PCSA Stock Ownership Filing

Processa Pharmaceuticals Director James R. Neal filed an amended Form 4 to correct previously reported beneficial ownership of restricted stock.

Summary

• An amendment to a Form 4 filing was submitted by James R. Neal, a Director of Processa Pharmaceuticals, Inc. (PCSA).
• The amendment retracts a prior Form 4, which was filed in error.
• The filing corrects the number of beneficially owned shares by James R. Neal.
• It reports the acquisition of 31,206 restricted stock units at a price of $0.
• These restricted stock units vest on the earlier of June 28, 2025, or the next annual meeting of stockholders, subject to certain distribution requirements.
• Following the corrected transaction, James R. Neal beneficially owns 36,275 derivative securities (restricted stock).

Sentiment

Score: 5

Explanation: The filing is a neutral administrative correction of a previous error in reporting beneficial ownership, with no direct positive or negative financial implications for the company's operations or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is an administrative correction of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides updated and corrected information regarding a director's beneficial ownership, ensuring transparency and accuracy in insider holdings.

Next Steps

• Restricted stock units are scheduled to vest on the earlier of June 28, 2025, or the next annual meeting of stockholders.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Form 4/A, Insider Trading, Beneficial Ownership, Restricted Stock, Director, SEC Filing